title: [Survival analysis of 530 HIV infected former unsafe commercial blood and plasma donors].
abstract: OBJECTIVE
  To investigate HIV survival time and it's influencing factors among former commercial blood and plasma donors engaged in unsafe blood donation practices in China.
  
  
  METHODS
  HIV/AIDS cases from 8 counties (districts) in 4 provinces confirmed prior to January 24, 2006 related with former commercial blood and plasma donors were selected and data regarding infection, AIDS progression, death, and influencing factors were retrospectively collected.
  
  
  RESULTS
  In 530 cases of HIV infection, 334 (63.0%) cases had developed AIDS, 168 (50.3%) had received antiretroviral therapy (ART), and 152 (29.0%) had died. For the 530 cases, there was an average (10.1 +/- 1.8) years of observation from time of infection. Among 166 AIDS patients not receiving ART, average survival was 9.1 years (95% CI: 9.1 - 9.4), with an 8 year survival rate of 52.0%. Among 168 AIDS patients receiving ART, average survival was 12.1 years (95% CI: 11.9 - 12.3), with a 12-year survival rate of 80.0%. In 3 years of ART, average survival was longer in the treatment group as compared to the no treatment group with a hazard ratio for death of 12.2. Univariate analysis showed a significant difference (P < 0.05) in AIDS patient average survival based on gender, age, location, ART status, and baseline CD(4)(+) T cells count. Results from multivariate COX-regression showed that highly active ant iretroriral therapy (HAART) was the strongest protective factor for prolonging AIDS patients' survival (HR = 13.3, P = 0.00).
  
  
  CONCLUSIONS
  Although there are many factors influencing AIDS patients survival, intervention with HAART is the principle measure to prolong survival and decrease the risk of death.
authors.affiliation: National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
authors.forename: Zhi-hui
authors.initials: ZH
authors.lastname: Dou
authors.forename: Lan
authors.initials: L
authors.lastname: Yu
authors.forename: Hong-xin
authors.initials: HX
authors.lastname: Zhao
authors.forename: Ye
authors.initials: Y
authors.lastname: Ma
authors.forename: Guo-ping
authors.initials: GP
authors.lastname: Peng
authors.forename: Li-xing
authors.initials: LX
authors.lastname: Lu
authors.forename: Zhi-He
authors.initials: ZH
authors.lastname: Li
authors.forename: Ji-hua
authors.initials: JH
authors.lastname: Fu
authors.forename: Fu-jie
authors.initials: FJ
authors.lastname: Zhang
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000401:mortality*; D000293:Adolescent; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001782:Blood Donors; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D055815:Young Adult